PA视讯·(中国区)官方网站-PA PlayAce

Pharmaceutical Manufacturing

In 2024, the revenue of the pharmaceutical manufacturing segment by Fosun Pharma amounted to 28,924 million.

To meet the unmet clinical needs, through an open and globally integrated pharmaceutical R&D ecosystem with independent R&D, co-development, license-in and industrial investment, Fosun Pharma focuses on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery.

By the end of 2024, the company had more than 80 projects for drugs under development, including innovator drugs, biosimilars. In 2024, the company applied for 220 patents in the pharmaceutical manufacturing segment, including 3 US patents and 18 PCT applications, with 66 patents granted.

Member Companies